Brokers Issue Forecasts for MIRM FY2025 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Mirum Pharmaceuticals in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings per share of ($1.55) for the year. The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($1.45) per share.

A number of other equities research analysts have also issued reports on the stock. Leerink Partners boosted their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an "outperform" rating in a report on Thursday, October 17th. HC Wainwright reissued a "buy" rating and set a $66.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Citigroup raised their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Finally, Robert W. Baird lifted their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $57.10.

Mirum Pharmaceuticals Price Performance

Shares of Mirum Pharmaceuticals stock traded up $1.93 on Thursday, hitting $48.65. The company had a trading volume of 428,526 shares, compared to its average volume of 492,863. Mirum Pharmaceuticals has a 52 week low of $23.14 and a 52 week high of $49.27. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The company has a market cap of $2.34 billion, a PE ratio of -24.08 and a beta of 0.98. The business has a 50-day simple moving average of $43.65 and a 200-day simple moving average of $41.40.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. The firm had revenue of $90.38 million for the quarter, compared to analysts' expectations of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. During the same period last year, the business posted ($0.57) earnings per share. The firm's revenue for the quarter was up 89.4% on a year-over-year basis.

Insider Activity at Mirum Pharmaceuticals

In related news, insider Joanne Quan sold 6,969 shares of the firm's stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $45.86, for a total value of $319,598.34. Following the completion of the sale, the insider now directly owns 5,649 shares in the company, valued at approximately $259,063.14. This trade represents a 55.23 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98. Following the transaction, the chief executive officer now directly owns 119,359 shares of the company's stock, valued at approximately $5,110,952.38. This trade represents a 5.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 19,706 shares of company stock worth $875,697 in the last ninety days. Company insiders own 22.87% of the company's stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Amalgamated Bank raised its stake in Mirum Pharmaceuticals by 60.8% during the second quarter. Amalgamated Bank now owns 1,357 shares of the company's stock worth $46,000 after acquiring an additional 513 shares in the last quarter. R Squared Ltd bought a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at approximately $69,000. Mirae Asset Global Investments Co. Ltd. increased its position in Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company's stock worth $67,000 after purchasing an additional 318 shares in the last quarter. Avanza Fonder AB bought a new position in Mirum Pharmaceuticals in the 4th quarter valued at approximately $189,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Mirum Pharmaceuticals in the third quarter valued at approximately $215,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.